Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and man...
November 22 2019 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it has extended its collaboration agreement
with GlaxoSmithKline plc (GSK), one of the world’s leading
healthcare companies, to raise awareness of the importance of
timely diagnosis of systemic lupus erythematosus (SLE), the most
common and severe form of lupus. At the center of the program are
the proprietary AVISE laboratory tests, which can facilitate early
diagnosis and management of SLE, a complex, incurable autoimmune
disease. The details of the agreement are confidential.
This extension follows a similar one-year extension that Exagen
and GSK entered into last year, and will continue to support the
shared goal of helping SLE patients shorten the time to their
diagnosis, which is nearly six years on average, and to facilitate
improved patient outcomes.
Ron Rocca, President and CEO of Exagen shared, “We’re pleased to
be working again with GSK, which demonstrates our ability to
collaborate with major pharmaceutical companies in a shared
commitment to improve patients’ lives. Having access to advanced
test result data such as the AVISE tests can support diagnosis,
prognosis, and monitoring of challenging conditions like SLE.”
About Exagen Inc.
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis. For further information
please visit www.exagen.com.
About GSK
GSK – a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
Forward Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding the expected benefits
or results of Exagen’s collaboration with GSK, and the performance
the AVISE laboratory tests and benefits of the test results data
obtained therefrom. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: Exagen’s commercial success depends upon attaining and
maintaining significant market acceptance of its testing products
and promoted therapeutics among rheumatologists, patients,
third-party payers and others in the medical community; risks
associated with maintaining third-party collaborations such as with
GSK and Exagen’s performance thereunder; and other risks described
in the Company’s prior press releases and in the Company’s filings
with the Securities and Exchange Commission, including under the
heading "Risk Factors" in the Company’s Registration Statement on
Form S-1 and any subsequent filings with the SEC. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and we undertake no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investors:Westwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
Company:Exagen Inc.Brian
McEvillybmcevilly@exagen.com760.560.1506
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024